ADR 851

Drug Profile

ADR 851

Latest Information Update: 06 Oct 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adria; Pfizer
  • Developer Adria
  • Class Antiemetics; Antipsychotics; Anxiolytics
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Nausea and vomiting

Most Recent Events

  • 02 Feb 2001 Profile reviewed but no significant changes made
  • 23 Jul 1996 No-Development-Reported for Anxiety disorders in USA (IV)
  • 23 Jul 1996 No-Development-Reported for Emesis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top